Neuroscience

#Amyotrophic lateral sclerosis (ALS) #Clinical trials #Neuroscience #NeuroSense

NeuroSense reports positive results from its ALS trial 

NeuroSense Therapeutics has reported additional positive data from its six-month double-blind Phase IIb PARADIGM trial of its lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS).   The PARADIGM trial’s secondary clinical efficacy outcome measure endpoints included Quality of Life and Survival. Consistent with the… Read More

#News

Neuroscience
#Autism #Gate Neurosciences #Neurodevelopmental disorders #Neuroscience #Preclinical investigations

Preclinical studies demonstrate potential of zelquistinel in autism

Robust efficacy in several preclinical models supports high translational potential of zelquistinel in autism and reflects broader opportunity across synaptic dysfunction disorders. Gate Neurosciences has announced the publication of new peer-reviewed research demonstrating the therapeutic potential of zelquistinel (GATE-251) to address symptoms of autism spectrum disorder… Read More

#News

#Antibodies #Bispecific Antibodies #FDA #Monoclonal antibodies #Neuroscience #Oncology

New DDW Highlights podcast: 11 March 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It was antibodies hitting the headlines this week, with the discovery of antibodies with… Read More

#News

CT scans of the brain
#Alzheimer's #Galimedix Therapeutics #Neurodegenerative disorders #Neuroscience #Preclinical investigations

New drug shows promising neuroprotective effects

Galimedix Therapeutics has announced data showing small molecule GAL-201 has neuroprotective and symptomatic alleviation potential in models of Alzheimer’s disease (AD). These new findings support previous studies where GAL-201 was characterised as a promising development candidate for the treatment of AD (Russ et. al. 2022). Read More

#News #Trending News

#Antibodies #Bispecific Antibodies #FDA #Monoclonal antibodies #Neuroscience #Oncology

This week in drug discovery (4-8 March) 

News round-up for 4-8 March by DDW Digital Content Editor Diana Spencer. It was antibodies hitting the headlines this week, with the discovery of antibodies with potential against a new influenza target, the launch of a Phase I trial to investigate a novel type of bispecific antibody, and… Read More

#News

A scientist examines brain scans on a large screen
#CNS #Neurology #Neuropsychiatric disorders #Neuroscience #Precision medicine #PrecisionLife

The era of precision neuroscience

Listen to this article on the DDW Podcast: Dr Steve Gardner, CEO of the computational biology company PrecisionLife, explores the challenges of achieving precision medicine in complex CNS conditions and explains how new precision neuroscience approaches are benefitting pharmaceutical companies who are again investing in the field to develop better treatments… Read More

#Exclusive Content

#FDA #Finance #GlobalData #Minerva Biosciences #Neuroscience #Schizophrenia

Minerva value plummets following FDA rejection of roluperidone

The stock market value of Minerva Biosciences has dropped nearly 60%, following the US Food and Drug administration (FDA) decision not to approve roluperidone for symptoms of schizophrenia. The company received a ‘Complete Response Letter’ from the FDA highlighting the clinical deficiencies in its new drug… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Human disease models #Interview #Neurology #Neuroscience #Stem cells

Putting human data at the centre of drug discovery

Listen to this article on the DDW Podcast: James Peach is the Co-Founder and CEO of Human Centric Drug Discovery (HCDD), an Oxford University spin-out improving neurology drug discovery by bringing more human data to the process. Peach shared his insight with DDW’s Megan Thomas. MT: In what ways can human… Read More

#Exclusive Content #Opinion

Neurons
#Anxiety disorder #Neurology #Neuroscience #Tokyo University of Science

Scientists identify potential new therapeutic target for anxiety

A new study has highlighted the role of specific neuronal circuits in the brain involved in the development of anxiety, and distinct mechanisms of action of the therapeutic delta opioid receptor (DOP) agonist KNT-127. Understanding the neural circuits and molecular mechanisms that trigger anxiety can aid… Read More

#News

Neurones in the brain
#Alzheimer's #Gene editing #Neurodegenerative disorders #Neuroscience

Advances in neuroscience drug discovery

Listen to this article on the DDW Podcast: Lu Rahman looks at neuroscience drug discovery – advances and challenges – and how breakthroughs in this field are helping address areas of unmet need.  Recent advances in biomarkers, research into the central nervous system and breakthroughs in human iPSC cell models, have bolstered… Read More

#Exclusive Content

Neuroscience Parkinson's disease
#Clinical trials #Gain Therapeutics #Neuroscience #Parkinson's

Restored motor function in mouse models of Parkinson’s disease  

Gain Therapeutics has announced preclinical data demonstrating that its clinical-stage GCase regulator GT-02287 provided neuroprotection and restored motor function in Parkinson’s disease models following delayed administration.   The data were accepted as a late-breaker abstract and was presented at the 20th Annual WORLDSymposium.  “We… Read More

#News

Neuroscience
#Cerebrotendinous xanthomatosis #Funding #Gene therapy #Neurodegenerative disorders #Neuroscience #Vivet Therapeutics

Funds advance gene therapy for cerebrotendinous xanthomatosis 

Vivet Therapeutics has received €4.9 million from the French government to advance the development of a gene therapy for the treatment of cerebrotendinous xanthomatosis (CTX), a rare neurodegenerative disease.   This funding is from the “Innovations in biotherapies” framework of the France Health Innovation Plan 2030 and specifically the acceleration strategy… Read More

#Business & Investment #News

Brain physiology
#Clinical trials #European Medicines Agency #Neuroscience #Synendos Therapeutics

EMA approves endocannabinoid system modulator trial

Synendos Therapeutics, has received approval from the European Medicines Agency (EMA) to commence the Phase I first-in-human clinical trial of its lead asset, SYT-510, a first-in-class inhibitor that modulates a newly identified drug target in the endocannabinoid system (ECS) to restore healthy brain physiology.   The randomised, double-blind, placebo-controlled study will… Read More

#News #Regulatory

Traumatic brain injury
#Brain injury #Neuroscience #Plant-based #Psychiatry #PTSD #Stanford University

Plant-based psychoactive drug treats traumatic brain injury

New research has found that plant-based psychoactive drug ibogaine improved depression, anxiety and functioning among veterans with traumatic brain injuries (TBI). TBI from head trauma or blast explosions are a leading cause of post-traumatic stress disorder (PTSD), anxiety, depression and suicide among veterans. Stanford… Read More

#News #Trending News

Human brain
#Clinical trial #Neuroscience #Newron Pharmaceuticals #Schizophrenia #Treatment resistance

“Highly encouraging” results for schizophrenia drug

Milan-based Newron Pharmaceuticals has reported “exceptional” one-year results from study 014/15 into evenamide as an add-on to antipsychotics for the management of treatment-resistant schizophrenia (TRS). The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of… Read More

#News

#Cancer research #Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Neuroscience #Oncology

DDW readers’ top drug discovery developments of 2023

DDW’s Diana Spencer takes a look at the breaking news stories that were most popular with DDW readers over the last year. Representing a dominant field of drug discovery, it isn’t surprising that breakthroughs in cancer research were popular with DDW readers in 2023, particularly strategies to overcome treatment resistance… Read More

#Exclusive Content